Loading...
•
Mar 31
Zevra Q1 2025 Earnings Report
Zevra Therapeutics reported its first quarter 2025 financial results, showing significant revenue growth driven by product sales and a strengthened cash position from the sale of a Priority Review Voucher.
Key Takeaways
Zevra Therapeutics reported a net revenue of $20.4 million for Q1 2025, a substantial increase from the previous year, primarily due to strong MIPLYFFA net revenue. Despite an operating loss, the company significantly improved its cash position to $217.0 million after the sale of its Pediatric Rare Disease Priority Review Voucher, positioning it for future commercial launches and development.
Net revenue for Q1 2025 was $20.4 million, a significant increase from $3.4 million in Q1 2024.
The company completed the sale of its Pediatric Rare Disease Priority Review Voucher for gross proceeds of $150 million, bolstering its cash balance to $217.0 million.
MIPLYFFA generated $17.1 million in net revenue, with 13 new prescription enrollment forms in Q1 2025, reaching 122 total, and market access at 38% of covered lives.
OLPRUVA saw 5 new patient enrollment forms in Q1 2025, bringing the total to 28 since July 2023, with market access increasing to 78% of covered lives.
Zevra
Zevra
Zevra Revenue by Segment
Revenue by Segment
MIPLYFFA Net Revenue
CapyFin.comOLPRUVA Net Revenue
CapyFin.comFrench EAP Arimoclomol Revenue
CapyFin.comAZSTARYS License Revenue
CapyFin.com Forward Guidance
Zevra Therapeutics is well-positioned to execute on its strategic priorities, including establishing MIPLYFFA as a cornerstone treatment, maximizing OLPRUVA's commercial opportunity, and supporting growth through its development pipeline, bolstered by a strong cash balance from the PRV sale.
Positive Outlook
- Bolstered cash balance from PRV sale provides ample resources and financial flexibility.
- Continued transformation into a patient-centric, commercial-stage rare disease therapeutics company.
- Strategic focus on establishing MIPLYFFA as a cornerstone treatment globally.
- Commitment to maximizing commercial opportunity with OLPRUVA.
- Support for growth through the development pipeline.
Challenges Ahead
- No specific negative forward guidance was provided in the report.
- The company disclaims any obligation to update forward-looking statements.
- Actual results may differ materially from expectations due to known and unknown uncertainties and risks.
- Reliance on forward-looking statements should be limited to the date of the press release.
- Future regulatory milestones and mid-single-digit royalties on out-licensed IP are potential, not guaranteed.